Search Result

Results for "

dyspepsia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) 5-HT Receptor (4) Adrenergic Receptor (1) Amyloid-β (2) Cholecystokinin Receptor (1) Cholinesterase (ChE) (5) Dopamine Receptor (4) Endogenous Metabolite (1) HIV (2) Isotope-Labeled Compounds (1) NO Synthase (1)
By Research Areas:	Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (7) Metabolic Disease (11) Neurological Disease (6)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B2089

Cinitapride	5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-121467

Acotiamide Z-338 free base; YM443 free base	Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-B2155

Acotiamide monohydrochloride trihydrate	Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC₅₀ of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-N1006

10-Hydroxyscandine	Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
10-Hydroxyscandine is an alkaloid from Melodinus tenuicaudatus. 10-Hydroxyscandine can be used for the research of hernia, dyspepsia, abdominal pain, and rheumatic heart .

HY-128386

Cinitapride monotartrate	5-HT Receptor Dopamine Receptor	Neurological Disease
Cinitapride monotartrate is a 5-HT_1A and 5-HT₄ agonist. Cinitapride monotartrate is also a 5-HT_2A and D₂ antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia .

HY-121467A

Acotiamide hydrochloride Z-338; YM443	Cholinesterase (ChE)	Others Metabolic Disease Inflammation/Immunology
Acotiamide hydrochloride is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC₅₀ of 1.79 μM. Acotiamide hydrochloride can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide hydrochloride has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-B2089R

Cinitapride (Standard)	5-HT Receptor Dopamine Receptor	Neurological Disease Metabolic Disease
Cinitapride (Standard) is the analytical standard of Cinitapride. This product is intended for research and analytical applications. Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research .

HY-B2155R

Acotiamide (monohydrochloride trihydrate) (Standard)	Cholinesterase (ChE)	Metabolic Disease Inflammation/Immunology
Acotiamide (monohydrochloride trihydrate) (Standard) is the analytical standard of Acotiamide (monohydrochloride trihydrate). This product is intended for research and analytical applications. Acotiamide monohydrochloride trihydrate is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with IC₅₀ of 1.79 μM. Acotiamide monohydrochloride trihydrate can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide monohydrochloride trihydrate has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .

HY-121467S

Acotiamide-d6 Z-338-d₆ free base; YM443-d₆ free base	Isotope-Labeled Compounds Cholinesterase (ChE)	Metabolic Disease
Acotiamide-d₆ is a deuterium labeled Acotiamide. Acotiamide is an orally active and first-in-class gastroprokinetic agent for the treatment of functional dyspepsia[1][2].

HY-117437

Azintamide Bilipurum; Oragalin	Cholecystokinin Receptor	Metabolic Disease
Azintamide (Bilipurum) can be used for the research of psoriasis vulgaris, dyspepsia and other conditions .

HY-N3329

Magnoloside A	Others	Others
Magnoloside A (compound 4) is a main phenylethanoid glycoside in Houpo. Magnoloside A can be used in the research of *functional dyspepsia* (FD)** .

HY-N0455B

L-Arginine (L-glutamate) 5+ Cited Publications (S)-(+)-Arginine (L-glutamate)	Endogenous Metabolite NO Synthase	Metabolic Disease
L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research .

HY-167675

R-137696	5-HT Receptor	Others
R-137696 is an orally active serotonin-1A (5-HT_1A) receptor agonist which relaxes the proximal stomach. R-137696 can be utilized in research related to functional dyspepsia .

HY-B1164A

Bromopride hydrochloride	Dopamine Receptor	Neurological Disease
Bromopride hydrochloride is a prokinetic drug with antiemetic activity. Bromopride hydrochloride is used to suppress nausea and vomiting, especially in the management of upper gastrointestinal dysmotility. Bromopride hydrochloride, as a dopamine D2 receptor antagonist, is clinically used to suppress functional dyspepsia, gastric retention and vomiting caused by various reasons .

HY-B2195

Aldioxa	Adrenergic Receptor	Metabolic Disease
Aidioxa has the ability to improve delayed gastric emptying in rats. It can partially improve delayed gastric emptying caused by clonidine or restraint stress. The allyltoin part of Aidioxa restores gastric emptying activity by antagonizing α-2 adrenergic receptors. Its aluminum hydroxide part is involved in restoring gastric compliance. Aidioxa can improve both delayed gastric emptying and impaired gastric compliance, both of which play an important role in functional dyspepsia (FD). Aidioxa is a candidate agent for inhibiting FD.

HY-B1588

Carbenoxolone	Amyloid-β HIV	Infection Neurological Disease Inflammation/Immunology
Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties . Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the treatment of chronic liver disease . Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD . Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop . Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself .

HY-B1588S

Carbenoxolone-d4	Amyloid-β HIV 11β-HSD	Infection Neurological Disease Inflammation/Immunology
Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0455B

L-Arginine (L-glutamate) 5+ Cited Publications (S)-(+)-Arginine (L-glutamate)	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite NO Synthase
L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research .

HY-N3329

Magnoloside A	Structural Classification Magnolia officinalis. Rehd. et Wils. Source classification Magnoliaceae Phenols Polyphenols Plants	Others
Magnoloside A (compound 4) is a main phenylethanoid glycoside in Houpo. Magnoloside A can be used in the research of *functional dyspepsia* (FD)** .

Cat. No.	Product Name	Chemical Structure

HY-121467S

Acotiamide-d6
Acotiamide-d₆ is a deuterium labeled Acotiamide. Acotiamide is an orally active and first-in-class gastroprokinetic agent for the treatment of functional dyspepsia[1][2].

HY-B1588S

Carbenoxolone-d4
Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties[3]. Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease[2]. Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD[1]. Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop[4].Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself[6].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks